Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading Canadian licensed cannabis producer, has recently made a significant move to expand its presence in the United States. The company has announced a minority investment of US $2 million in Steady State LLC, operating as Open Book Extracts (OBX), as part of its first Jupiter Investment. This strategic investment showcases Organigram’s commitment to the burgeoning US cannabis market.
Based in Roxboro, within North Carolina’s Research Triangle, OBX is a renowned legal cannabinoid ingredient producer, focusing on simplifying its clients’ supply chains by offering a range of one-stop formulation and finished goods manufacturing services. With this new collaboration, Organigram aims to enhance its capabilities in cannabinoid-based product development and manufacturing, while seizing opportunities presented by the burgeoning US cannabis sector.
The partnership with OBX complements Organigram’s ongoing efforts to establish a strong foothold in the US cannabis industry. By leveraging OBX’s expertise in legal cannabinoid production, Organigram gains access to high-quality, compliant ingredients that can be utilized in its extensive portfolio of cannabinoid-based products. This investment also aligns with Organigram’s strategy to expand its market share and enhance its global supply chain within the growing legal cannabis sector.
Organigram’s decision to invest in OBX reflects its confidence in the potential of the US cannabis market, especially amid increasing legalizations and hemp regulations across various states. By partnering with an established US-based manufacturer, Organigram can tap into new distribution channels and capitalize on a broader customer base.
The convertible note structure of the investment provides Organigram with potential future advantages. In addition to financial gains, the company may have the opportunity to convert its loan into equity if certain conditions are met. This positions Organigram to benefit from future growth and success of OBX, creating a mutually beneficial collaboration.
Greg Engel, CEO of Organigram, expressed his excitement about the investment, stating, We are thrilled to partner with OBX as they are an ideal strategic fit and complement Organigram’s value-added products and services strategy. This investment aligns with our strategic growth priorities and will contribute to the development of innovative cannabinoid formulations for both the US and international markets.
As Organigram continues to expand its presence in the US, the investment in OBX showcases the company’s dedication to unlocking the full potential of the cannabis industry. With this strategic move, Organigram aims to strengthen its position as a pioneer in cannabinoid-based product development and manufacturing, while capitalizing on the growing demand for legalized cannabis products worldwide.
Comments